CoChat
Sign Up
Cited by 401Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo controlled trial in asymptomatic antiphospholipid antibody-positive individuals.

Erkan, Doruk, Harrison, Melanie J., Levy, Roger, Peterson, Margaret, Petri, Michelle, Sammaritano, Lisa, Unalp‐Arida, Aynur, Vilela, Veronica, Yazici, Yusuf, Lockshin, Michael D.·2007·Arthritis & Rheumatism
DOI 10.1002/art.22663
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events). METHODS: The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA) study was a multicenter, randomized, double-blind, placebo-controlled clinical trial in which asymptomatic, persistently aPL-positive individuals were randomized to receive a daily dose of 81 mg of aspirin or placebo. In a separate observational and parallel study, asymptomatic, persistently aPL-positive individuals who were taking aspirin or declined randomization were followed up prospectively. RESULTS: In the APLASA study, 98 individuals were randomized to receive aspirin or placebo (mean +/- SD followup period 2.30 +/- 0.95 years), of whom 48 received aspirin and 50 received placebo. In the observational study, 74 nonrandomized individuals were followed up prospectively (mean +/- SD followup period 2.46 +/- 0.76 years); 61 received aspirin and 13 did not. In the APLASA study, the acute thrombosis incidence rates were 2.75 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for the placebo-treated subjects (hazard ratio 1.04, 95% confidence interval 0.69-1.56) (P = 0.83). Similarly, in the observational study, the acute thrombosis incidence rates were 2.70 per 100 patient-years for aspirin-treated subjects and 0 per 100 patient-years for those not treated with aspirin. All but 1 patient with thrombosis in either study had concomitant thrombosis risk factors and/or systemic autoimmune disease at the time of thrombosis. CONCLUSION: Our results suggest that asymptomatic, persistently aPL-positive individuals do not benefit from low-dose aspirin for primary thrombosis prophylaxis, have a low overall annual incidence rate of acute thrombosis, and develop vascular events when additional thrombosis risk factors are present.

Overview

Integrity signals

Registry

Crossref · 10.1002/art.22663

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 46 references

Research works printed but not linked: 2

  1. Papadopolous E, 1999, Antiphospholipid antibodies and venous thrombosis (VT) in SLE, Arthritis Rheum, 42, S369
  2. Kaul M, 2006, Assessment of the 2006 revised antiphospholipid syndrome (APS) classification criteria, Arthritis Rheum, 54, S796

Cited by

Sorted by citations

See all 401

Related

Metadata

Authors
Erkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D.
Affiliations
  • Hospital for Special Surgery (US)
  • Hospital Universitário Pedro Ernesto (BR)
  • Johns Hopkins University (US)
ORCID
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2007-06-28
Volume
56
Issue
7
Pages
2382-2391
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
DOI
10.1002/art.22663
OpenAlex
W2068492012
Cited by
401
References
46
Citations by year
2026: 5 · 2025: 8 · 2024: 12 · 2023: 16 · 2022: 10 · 2021: 16 · 2020: 16 · 2019: 18 · 2018: 19 · 2017: 23 · 2016: 24 · 2015: 16 · 2014: 27 · 2013: 32 · 2012: 37
FWCI
21.25
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Arthritis & Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
aspirin, antiphospholipid syndrome, antiphospholipid antibodies, thromboprophylaxis, low-dose aspirin, thrombosis risk factors, vascular events
MeSH terms
Adult, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Double-Blind Method, Ethnicity, Female, Humans, Male, Middle Aged, Placebos, Thrombosis, Antiphospholipid Syndrome, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review